Abstract
BackgroundThe aim of this study is to quantify the burden caused by viral hepatitis in China from 1990 to 2016.MethodsData from the GBD 2016 study were extracted to calculate incidence, prevalence and disability-adjusted life years (DALYs). Trends in DALYs were assessed in 33 provinces/regions.ResultsFrom 1990 to 2016, the total incidence of hepatitis decreased by 88.5%. However, the prevalence of hepatitis (counts in thousands), increased by 37.6% from 153,856 (95% UI: 136,047-172,319) in 1990 to 211,721 (95% UI: 179,776-240,981) in 2016, with age-standardized prevalence rates changing slightly. The number and age-standardized rates of prevalence increased by 35.9 and 1.6% for hepatitis B, respectively, and by 81.8 and 30.4% for hepatitis C. Guangxi, Guangdong and Hainan had the highest age-standardized prevalence rates (≥16,500 per 100,000). Tibet, Qinghai and Gansu had the highest age-standardized DALYs rates (≥40 per 100,000). The largest absolute number of DALYs was observed in the 15–49 year age group in 2016. The highest rate of DALYs occurred in males aged 50–69 years and in females aged ≧70 years.ConclusionThe incidence and DALYs of viral hepatitis decreased dramatically from 1990 to 2016. However, the prevalence still remains at a high level, which may result in heavy burdens in the future.
Highlights
The aim of this study is to quantify the burden caused by viral hepatitis in China from 1990 to 2016
Viral hepatitis can be caused by a series of viruses, namely, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E
Incidence and prevalence We used over 110,000 outcomes of incidence, prevalence, years lived with disability (YLDs), years of life lost (YLLs) and disability-adjusted life years (DALYs) for hepatitis and the following three levels: 29 age groups; 33 provinces/regions; and 7 individual years from 1990 to 2016
Summary
The aim of this study is to quantify the burden caused by viral hepatitis in China from 1990 to 2016. Viral hepatitis, which results from inflammation of the liver, is a major public health concern [1,2,3,4]. Due to the large population base in China, there are still many cases of hepatitis. In addition to seriously threatening human health, viral hepatitis brings heavy economic burdens to patients. The direct economic loss caused by hepatitis B in China is at least 500 billion RMB every year. Despite the large burden of disease, investments in hepatitis remain limited at the national and international levels when compared with some other major infectious diseases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
